Visual outcomes and choroidal thickness associated with human leukocyte antigen DRB1*04 in unclassifiable uveitis in Japanese patients.
Asian patients
HLA-DRB1*04
Human leukocyte antigen
Non-infectious uveitis
Unclassifiable uveitis
Visual acuity
Journal
BMC ophthalmology
ISSN: 1471-2415
Titre abrégé: BMC Ophthalmol
Pays: England
ID NLM: 100967802
Informations de publication
Date de publication:
28 Dec 2021
28 Dec 2021
Historique:
received:
04
05
2021
accepted:
15
12
2021
entrez:
29
12
2021
pubmed:
30
12
2021
medline:
31
12
2021
Statut:
epublish
Résumé
Human leukocyte antigen (HLA) and immunity are related. Uveitis is also closely related to immunity. For example, the common presence of human leukocyte antigen (HLA)-DRB1*04 in the immune response is well known. The aim of this study was to investigate the relationship between visual prognosis and various HLA alleles before and after therapy in patients with unclassifiable uveitis, excluding those with Vogt-Koyanagi-Harada (VKH) disease. This retrospective case series included 42 eyes from 22 consecutive patients with unclassifiable uveitis, excluding those with VKH disease. Visual acuity (VA), sex, refractive error, central retinal thickness (CRT), central choroidal thickness (CCT), and duration from onset to treatment were measured at initial and 6-month visits. Mean values of parameters were compared at each visit. Genotyping was performed by polymerase chain reaction amplification with sequence-specific primers. DRB1*04 showed a dominant change. No significant difference was observed in the other alleles. In DRB1*04, The mean differences in initial CCT, 6-month CCT, and 6-month VA showed statistically significant difference was found in best-corrected visual acuity (BCVA) between DRB1*04+ and DRB1*04- at the first visit. BCVA values at baseline and at the final visit were 0.13 ± 0.29 and 0.20 ± 0.36 in the DRB1*04+ and 0.00045 ± 0.20 and - 0.058 ± 0.11 in the DRB1*04- groups(p = 0.00465). Central Choroidal Thickness (CCT) values pretreatment and at the final visit after treatment were (pretreatment:361.00 ± 361.0 μm,after treatment: 286.00 ± 106.53 μm, p = 0.0174) in the DRB1*04+ group, and (pretreatment:281.3 ± 139.68 μm,after treatment:223.85 ± 99.034 μm, p = 0.0426) in the DRB1*04- group, respectively, indicating changes between baseline and the final visit. CCT was significantly greater in the DRB1*04+ group at both the initial visit and at 6 months. Multivariate analysis showed a significant difference between the presence or absence of DRB1*04 and sex. HLA-DRB1*04 allele may affect visual prognosis and CCT in unclassifiable uveitis.
Identifiants
pubmed: 34963463
doi: 10.1186/s12886-021-02222-9
pii: 10.1186/s12886-021-02222-9
pmc: PMC8715637
doi:
Substances chimiques
HLA-DRB1 Chains
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
457Informations de copyright
© 2021. The Author(s).
Références
Ophthalmology. 1983 Jan;90(1):76-95
pubmed: 6338439
Front Immunol. 2019 May 10;10:1067
pubmed: 31134098
Int J Ophthalmol. 2016 Apr 18;9(4):561-6
pubmed: 27162729
Lancet. 1991 Dec 14;338(8781):1501-4
pubmed: 1683928
Invest Ophthalmol Vis Sci. 2019 Apr 1;60(5):1714-1723
pubmed: 31013344
Retina. 2019 Aug;39(8):1607-1612
pubmed: 29689026
Ocul Immunol Inflamm. 2009 May-Jun;17(3):160-9
pubmed: 19585358
Ophthalmology. 1990 Sep;97(9):1137-42
pubmed: 2234843
J Immunol. 1993 Dec 15;151(12):7284-92
pubmed: 8258725
Am J Ophthalmol. 2018 Oct;194:35-45
pubmed: 30026083
BMC Ophthalmol. 2019 Nov 7;19(1):214
pubmed: 31699055
Arthritis Rheumatol. 2019 Oct;71(10):1642-1650
pubmed: 31038287
Br J Ophthalmol. 2008 Jul;92(7):976-80
pubmed: 18577650
Br J Ophthalmol. 2018 Feb;102(2):215-219
pubmed: 28607176
Ophthalmology. 2004 Mar;111(3):491-500; discussion 500
pubmed: 15019324
Lancet. 1991 Dec 14;338(8781):1498-501
pubmed: 1683927
Lancet. 1983 Nov 12;2(8359):1111-5
pubmed: 6138646
Orphanet J Rare Dis. 2016 Mar 24;11:29
pubmed: 27008848
Am J Ophthalmol. 2001 May;131(5):647-52
pubmed: 11336942
Tissue Antigens. 2009 Jan;73(1):1-8
pubmed: 19017300
Nat Rev Immunol. 2005 Oct;5(10):793-806
pubmed: 16200082
Am J Ophthalmol. 2015 Nov;160(5):1034-1043.e1
pubmed: 26210861
Inflamm Bowel Dis. 2017 Dec;23(12):2121-2133
pubmed: 29084077
Exp Eye Res. 2020 Jan;190:107853
pubmed: 31669406
Tissue Antigens. 2015 Apr;85(4):252-9
pubmed: 25789826
Proc Natl Acad Sci U S A. 1989 Dec;86(24):10049-53
pubmed: 2481309
BMC Ophthalmol. 2018 Aug 2;18(1):189
pubmed: 30068311
Curr Eye Res. 2015 Feb;40(2):213-25
pubmed: 25153829
Invest Ophthalmol Vis Sci. 1991 Dec;32(13):3131-41
pubmed: 1748544
Ocul Immunol Inflamm. 2021 Jul 4;29(5):976-981
pubmed: 32068467
Intern Med. 2019 May 1;58(9):1199-1207
pubmed: 30626832
Jpn J Ophthalmol. 2007 Jan-Feb;51(1):41-4
pubmed: 17295139
Prog Retin Eye Res. 2018 May;64:1-55
pubmed: 29229445
Acta Ophthalmol. 2015 Nov;93(7):e585-92
pubmed: 25529388
Invest Ophthalmol Vis Sci. 2005 Jul;46(7):2465-71
pubmed: 15980237
Lancet. 1990 May 5;335(8697):1078-80
pubmed: 1970380